Discover more from PsyMed Ventures Newsletter
Developing Non-Hallucinogenic Psychedelics: Bryan Roth
Business Trip by PsyMed Ventures, a podcast about the business of psychedelics
Welcome back to Business Trip by PsyMed Ventures, a podcast about the business of psychedelics! 🍄
In our latest episode, Greg and Matias engage in an insightful discussion with Dr. Bryan Roth, the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine, and the founder of the Roth Lab.
Dr. Roth’s lab is on the cutting edge of researching the interaction between brain cell receptors and compounds like LSD and psilocybin. Their findings have the potential to revolutionize the treatment of psychiatric disorders, potentially creating new forms of psychedelics that offer the therapeutic benefits without hallucinations or other side effects.
Roth Labs recently received a $26 million grant from DARPA, a US government agency, to explore the potential of non-hallucinogenic psychedelics. Onsero, a new preclinical neurobiology startup, has licensed Dr. Roth's research to bring these novel compounds to market.
In this episode, we discuss:
The therapeutic effects of psychedelic and non-hallucinatory compounds
The transition from animal model studies to human trials
The journey of turning deep academic research into viable commercial entities
Once you've finished the episode, we'd love to hear your thoughts! Tweet us at @psymedventures to share your views.
P.S. Do you know someone who would enjoy the Business Trip by PsyMed Ventures podcast? Feel free to share this newsletter by clicking the link below and hitting the ❤️ button on this post to help us reach more people on Substack 🙏
Business Trip by PsyMed Ventures is a podcast about psychedelic startups. Each episode features a new company in the field, ranging from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem.
Thanks for listening,